cediranib plus olaparib increases progression-free survival in recurrent ovarian cancer
Published 10 years ago • 396 plays • Length 4:19Download video MP4
Download video MP3
Similar videos
-
4:52
cediranib plus olaparib significantly increases pfs in recurrent ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
2:13
dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
8:09
olaparib improves disease-free survival in high-risk early-stage her2-negative breast cancer wit...
-
6:21
update on olaparib in ovarian cancer
-
6:49
olaparib with or w/out cediranib vs standard of care for recurrent platinum-sensitive ovarian cancer
-
3:24
solo-1: olaparib or placebo for patients with newly diagnosed brca-mutated advanced ovarian cancer
-
4:23
comment: parp inhibitor olaparib plus bevacizumab in women with ovarian cancer
-
0:54
dr. ursula matulonis on phase iii trials examining cediranib plus olaparib in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
6:03
olaparib maintenance for recurrent ovarian cancer
-
5:32
parp inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without...
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
0:55
a study of olaparib and cediranib in ovarian cancer
-
10:34
solo1: maintenance olaparib in advanced brca ovarian cancer
-
2:31
should all platinum sensitive patients recieve parp inhibitors?
-
4:14
olaparib continues to show positive results in advanced ovarian cancer - 7 year data